Ann: Rhythm Maintains Ongoing ISO13485 Certification, page-24

Comparing Rhythm with the maker of cologuard, Exact Sciences, the latter is probably where Rhythm wants to be in a few years: ColoSTAT being a product already well established on the market and with a portfolio or pipeline of other products being commercialised. Worth emphasising that Rhythm has a market capitalisation of about A$270m and Exact Sciences has a market cap closer to A$20b. Even if we have to cope some dilution as the company grows, the potential gains are significant. For me, it all depends on study 7 (and not being taken over).